Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.

Also called NCT05440591

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05440591
Other papers using this trial's data
  • First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial Diabetes, obesity & metabolism, 2026-09 DOI, PubMed 42396722, PMC13449050 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Singapore (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05440591. Randomized; no masking; primary purpose treatment. Start 2019-04-01 (actual); primary completion 2023-05-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
Acronym
DMVascular
Condition
Diabetes
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
MetFORMIN 500 Mg Oral Tablet
Intervention (Drug)
Dapagliflozin / metFORMIN Pill
Lead sponsor
Tan Tock Seng Hospital (class: other)

Record details

Record id
cardio:ct-nct05440591
Content hash
2f95d50537c01f85c80e3a7f90a41c828062bb3c382e965b4f3b6d4eb0d81221